MedTrace Logo

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

NCT01955733 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2018-01-18

Study results available
· View outcomes & findings →

Summary

The primary objective of this trial is to evaluate the long-term safety of BI 695500 in adult patients with moderately to severely active rheumatoid arthritis (RA) who have successfully completed treatment in Trial 1301.1.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

BI 695500

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
82 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-11-18
Completion
2016-11-07

Countries

  • United States
  • Belgium
  • Bulgaria
  • Germany
  • Greece
  • Netherlands
  • Poland
  • Portugal
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01955733 on ClinicalTrials.gov